Search clinical trials for: Some IIIA Non-Small Cell Lung Cancer (NSCLC)

Total 159553 results

Genentech, Inc.

Completed

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Non-Small Cell Lung Cancer

United States, Spain, Argentina, Israel, Hong Kong, Thailand, Australia, Belgium, Brazil, Bulgaria, Italy, Mexico, Philippines, Romania, Singapore, Taiwan, United Kingdom
National Cheng-Kung University Hospital

Unknown

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Non-Small Cell Lung Cancer

Taiwan
Lady Davis Institute

Withdrawn

Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients (CH:II)

Metastatic NSCLC

Canada
Betta Pharmaceuticals Co., Ltd.
Fudan University

Unknown

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Brain Metastases | Lung Cancer, Nonsmall Cell

China
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
University of Louisville
James Graham Brown Cancer Center

Terminated

The Effect of Berries on Lung Cancer Tumors

Non Small Cell Lung Cancer

United States
University of Miami

Terminated

Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, United Kingdom
Universitair Ziekenhuis Brussel

Unknown

Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System

Non-Small Cell Lung Carcinoma

Belgium
Exelixis

Completed

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
AstraZeneca

Completed

A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients (MAPSY)

Non Small Cell Lung Cancer

Sweden
SCRI Development Innovations, LLC
AstraZeneca

Completed

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Lung Cancer
AstraZeneca

Completed

Phase II Iressa & Carbo/Gem in NSCLC

Carcinoma, Non-Small-Cell Lung

Canada
Regeneron Pharmaceuticals

Not yet recruiting

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Shanghai Miracogen Inc.

Not yet recruiting

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Non-small- Cell Lung Cancer (NSCLC)

China
Stanford University

Completed

Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Lung Cancer

United States
AstraZeneca

Completed

Phase II Iressa Versus Vinorelbine (INVITE)

Non-Small-Cell Lung Carcinoma

Czech Republic, Italy, Korea, Republic of, South Africa, United Kingdom, Germany, Australia, Taiwan, France, Brazil
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
Tang-Du Hospital

Recruiting

A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

Non Small Cell Lung Cancer

China
Beijing Friendship Hospital
Newish Technology (Beijing) Co., Ltd.

Unknown

Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

China
Genelux Corporation
Newsoara Biopharma Co., Ltd.

Not yet recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25))

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Shanghai Chest Hospital

Recruiting

Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

Non-small-cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Vestre Viken Hospital Trust
Odense University Hospital; Karolinska University Hospital; Oslo University Hospital and other collaborators

Recruiting

Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities (SOLUCOM)

Cancer | Lung Cancer | NSCLC Stage IV | Mutation | NSCLC, Stage III | Lung Cancer Stage IV | Cancer, Lung

Norway
Swedish Lung Cancer Study Group

Recruiting

Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC (MARS)

Quality of Life | Non Small Cell Lung Cancer | Radiotherapy | Stage IV Non-small Cell Lung Cancer

Sweden
University of Vermont
Johnson & Johnson

Recruiting

Intratumoral Cisplatin for Resectable NSCLC

Non-Small Cell Lung Cancer

United States
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Technical University of Munich

Completed

Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

NSCLC Stage IIIA/B

Germany
Korea Institute of Oriental Medicine

Recruiting

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of
Xiaorong Dong

Recruiting

Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Early Stage Non-small Cell Lung Cancer

China
Beijing Pearl Biotechnology Limited Liability Company

Active, not recruiting

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) (KUNPENG-2)

Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

Non-small Cell Lung Cancer(NSCLC)

China
Sun Yat-sen University

Unknown

Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer

Bevacizumab | Brain Metastases | Non Squamous Non-small Cell Lung Cancer

China
Biotech Pharmaceutical Co., Ltd.

Withdrawn

Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
CytRx

Terminated

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion

United States, Mexico, India, Ukraine, Bulgaria, Russian Federation
NYU Langone Health

Recruiting

Daratumumab in STK11 Mutated NSCLC

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

United States
Olivia Newton-John Cancer Research Institute
Merck Sharp & Dohme LLC; Viralytics

Active, not recruiting

Pembrolizumab + CVA21 in Advanced NSCLC

Non-Small Cell Lung Cancer

Australia
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
Regeneron Pharmaceuticals

Recruiting

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Advanced NSCLC

United States
Third Military Medical University

Unknown

Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression (GTCA)

Non-small Cell Lung Cancer

China
Sanofi

Completed

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

Cancer | Non-small Cell Lung Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Switzerland, Australia
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Hoffmann-La Roche

Completed

A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device. (Lupa-01)

Non-Small Cell Lung Cancer (NSCLC)

Spain

Search clinical trials for: Some IIIA Non-Small Cell Lung Cancer (NSCLC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations